BD named Vitor Roque as chief financial officer Thursday, ending the medtech company’s seven-month search for a permanent replacement for Chris DelOrefice. In October, DelOrefice told BD that he ...
8don MSN
BD forecasts FY 2026 adjusted EPS of $12.52-$12.72 while reaffirming low-single-digit revenue growth
Q2 fiscal 2026 Management view "We delivered a solid second quarter with revenue, adjusted margins and adjusted EPS all ahead of our expectations" (President, CEO & Chairman Thomas Polen), adding, ...
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
Travis Steed, the medical device analyst at Bank of America. Next up, we have Becton, Dickinson, Tom Polen, CEO; and Vitor Roque, the newly announced CFO. I think you've been to Vegas a couple of ...
StockStory.org on MSN
BD’s (NYSE:BDX) Q1 CY2026 sales beat estimates
Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results